2019
DOI: 10.1007/s12325-019-01054-w
View full text |Buy / Rent full text
|
Sign up to set email alerts
|
Yehuda Handelsman

Abstract: Diabetes-related complications including cardiovascular disease, heart failure (HF), chronic kidney disease, retinopathy, and neuropathy are associated with a high burden of disease. Early initiation of glucose-lowering therapy in patients with type 2 diabetes to achieve glycemic control is important for reduction of not only microvascular risk but also of CV (cardiovascular) risk. Clinical studies have indicated that early achievement of glycemic targets is likely to have the greatest effect on preventing mic… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
8
0

Year Published

2020
2020
2022
2022

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 10 publications
(8 citation statements)
references
References 98 publications
(160 reference statements)
0
8
0
Order By: Relevance
“…Taken together, the results of the present study were comparable with those of previous studies [ 1 3 ]. The early initiation of SGLT-2 inhibitor therapy should be considered in patients with T2D and established CVD [ 50 ].…”
Section: Discussionmentioning
confidence: 99%
“…Taken together, the results of the present study were comparable with those of previous studies [ 1 3 ]. The early initiation of SGLT-2 inhibitor therapy should be considered in patients with T2D and established CVD [ 50 ].…”
Section: Discussionmentioning
confidence: 99%
“…[7][8][9] Many studies have also demonstrated that the use of sodium-glucose cotransporter 2 (SGLT2) inhibitor results in good glycemic control and low rate of diabetic complications. [10][11][12] However, the association between SGLT2 inhibitor and ID remains unclear. Therefore, we conducted a retrospective cohort study to explore the relationship between SGLT2 inhibitors and ID in the general Taiwanese population.…”
Section: Introductionmentioning
confidence: 99%
“…A persistently elevated level of HbA1c increases the risk of vascular complications, such as coronary disease, heart attack, stroke, heart failure, kidney failure, blindness, erectile dysfunction, neuropathy, gangrene, gastroparesis, and short-term complications of surgery such as poor wound healing. [ 9 , 10 ]…”
Section: Introductionmentioning
confidence: 99%
“…Specific drugs include dapagliflozin (DAPA), canagliflozin (CANA), empagliflozin (EMPA), ertugliflozin (ERTU), and sotagliflozin (SOTA). [ 9 , 10 ] SGLT inhibitors are commonly used as second-line hypoglycemic agents in clinical practice. [ 11 ]…”
Section: Introductionmentioning
confidence: 99%